BioSpace News Archive

RLDatix, a leading provider of governance, risk and compliance (GRC) solutions that drive patient safety, quality improvement and harm reduction in healthcare, today demonstrated its continued commitment to risk management and patient safety by announcing its participation in numerous events at the American Society for Health Care Risk Management’s (ASHRM) annual conference

Qrons Inc. (OTCQB: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries, including concussions and penetrating injuries, announced today that it has entered into an Intellectual Property License Agreement (the “Agreement”) with Dartmouth College for an exclusive world-wide license of Intellectual Property related to 3D printable materials in the fields of human and animal health.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced its participation at two upcoming investor conferences.

Pharmaceutical and biopharmaceutical manufacturers can now verify the identity of ionic salts in the warehouse in a matter of seconds with a new portable X-ray fluorescence (XRF) analyzer.

Hoth Therapeutics, Inc. (Nasdaq: HOTH) today announced that the company has made a donation to the National Eczema Association in order to bring continued awareness to National Eczema Awareness Month this Octobe

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced findings from an open-label, single-arm pilot study, which examined the impact of SkinTE™, a novel human cellular and tissue-based product derived from a patient’s own skin, in closing venous stasis leg ulcers (VLUs) following failure of conventional treatments.

There is nearly a 40% chance of overdiagnosing chronic obstructive pulmonary disease (COPD) when spirometry is not combined with bronchodilator (BD) testing, often missing asthma and asthma-COPD overlap syndrome (ACOS), according to Srinadh Annangi, MD, from the University of Kentucky, School of Medicine, who will present the study findings at the CHEST Annual Meeting 2019 in New Orleans

Patients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) who were treated with macitentan had similar therapeutic and safety results as patients with PAH from both idiopathic PAH (IPAH) and heritable PAH (HPAH), which is caused by a genetic mutation that runs in families, according to Vallerie McLaughlin, MD, FCCP, from the University of Michigan, Ann Arbor, who will present the study findings at the CHEST Annual Meeting 2019 in New Orleans.

Patients with lung blood clots who smoke are more likely to be readmitted for lung blood clots than nonsmokers, according to Kam Sing Ho, MD, from Mount Sinai St. Luke’s and Mount Sinai West in New York City, who will present the study findings at the CHEST Annual Meeting 2019 in New Orleans.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for UX007 (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), a group of genetic disorders in which the body is unable to convert long-chain fatty acids into energy.